Research
William Blair Initiates Zentalis Pharmaceuticals at Outperform
Zentalis Pharmaceuticals (ZNTL) has an average rating of overweight and mean price target of $7.30, according to analysts polled by FactSet.
$ZNTL
$ZNTL
8 stories mentioning ZNTLUpdated 7d ago
Every FINWIRES story that references ZNTL, newest first.
What are analysts saying about ZNTL?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on ZNTL?
Insider Trading
Zentalis Pharmaceuticals Insider Bought Shares Worth $15,172,500, According to a Recent SEC Filing
Group Walters, 10% Owner, on August 14, 2026, executed a purchase for 4,335,000 shares in Zentalis Pharmaceuticals (ZNTL) for $15,172,500. Following the Form 4 filing with the SEC, Walters has control over a total of 17,844,973 common shares of the company, with 17,844,973 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1725160/000121390026091823/xslF345X05/ownership.xml
$ZNTL
Sectors
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) lost 0.5%.In corporate news, Luigi Mangione is expected to plead guilty to federal charges related to the killing of former UnitedHealth (UNH) executive Brian Thompson, according to his lawyer, multiple media outlets reported Friday. UnitedHealth shares were up 0.8%.Valneva (VALN) shares jumped 25% after the company and Pfizer (PFE) said the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate, starting the regulatory review process. Pfizer shares were fractionally lower.Eton Pharmaceuticals (ETON) shares surged 41%. The company late Thursday reported Q2 adjusted earnings and revenue above market expectations and raised full-year 2026 sales guidance.Zentalis Pharmaceuticals (ZNTL) shares fell past 12% in Friday trading, a day after the company priced an offering of 23 million shares at $3.50 each, targeting about $80.5 million in gross proceeds.
$ETON$PFE$UNH$VALN$ZNTL
Sectors
Sector Update: Healthcare
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) lost 0.5%.In corporate news, Zentalis Pharmaceuticals (ZNTL) shares fell past 14% in Friday trading, a day after the company priced an offering of 23 million shares at $3.50 each, targeting about $80.5 million in gross proceeds.
$ZNTL
Wire
Update: Zentalis Pharmaceuticals Shares Fall After Pricing $80.5 Million Offering to Fund Clinical Pipeline
(Updates with the company's stock move in the headline and first paragraph.)Zentalis Pharmaceuticals (ZNTL) shares were down about 16% in Friday trading, a day after the company priced an offering of 23 million shares at $3.50 each, targeting about $80.5 million in gross proceeds.The company granted underwriters a 30-day option to purchase up to an additional 3.45 million shares.Net proceeds, together with existing cash, cash equivalents and marketable securities, are intended to finance, among other things, clinical trials, preclinical studies, and regulatory filings.Zentalis is selling all of the common stock in the offering, which is expected to close on Aug. 17.Price: $3.51, Change: $-0.65, Percent Change: -15.54%
$ZNTL
Wire
Wedbush Adjusts Price Target on Zentalis Pharmaceuticals to $5 From $4, Maintains Neutral Rating
Zentalis Pharmaceuticals (ZNTL) has an average rating of overweight and mean price target of $7.33, according to analysts polled by FactSet.Price: $4.81, Change: $-0.19, Percent Change: -3.80%
$ZNTL
Wire
Zentalis Shares Rise After Mizuho Initiates Coverage at Outperform
Zentalis Pharmaceuticals (ZNTL) shares rose nearly 12% in Friday afternoon trading after Mizuho initiated coverage of the stock with an outperform rating and a price target of $8.Trading volume stood at over 2.5 million shares, compared with a daily average of about 1.1 million.Price: $5.11, Change: $+0.54, Percent Change: +11.86%
$ZNTL
Research
Mizuho Initiates Zentalis Pharmaceuticals at Outperform With $8 Price Target
Zentalis Pharmaceuticals (ZNTL) has an average rating of overweight and mean price target of $6.50, according to analysts polled by FactSet.
$ZNTL
